ArticleMolecular medicine reports2026
ZBTB16 upregulation maintains copper homeostasis to support esophageal tumor progression.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc finger and BTB domain‑containing protein 16 (ZBTB16) plays diverse roles in a number of different cancer types, but its function and mechanism in esophageal cancer remain ambiguous. The present study was, to the best of our knowledge, the first demonstration that ZBTB16 was highly expressed in esophageal cancer tissues and cell lines. Knockdown of ZBTB16 significantly inhibited the proliferation and migration of esophageal cancer cells. Furthermore, ZBTB16 silencing increased the rate of cell death in esophageal cancer cells and induced mitochondrial membrane potential loss, intracellular copper accumulation and elevated oxidative stress. Mechanistically, knockdown of ZBTB16 downregulated the expression of ATPase copper‑transporting α and ATPase copper‑transporting β (ATP7B), while upregulating copper uptake protein 1 and ferredoxin. The present study further demonstrated that ZBTB16 knockdown increased the production of reactive oxygen species, which was partially rescued by ATP7B overexpression. In a mouse xenograft model of esophageal cancer, ZBTB16 knockdown markedly suppressed tumor growth, significantly reduced tumor weight and volume and notably altered the expression of cuproptosis‑related proteins
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.